Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer: What have we Learned from Prospective Trials and What Does the Future Hold?

Shankar Siva1 Division of Radiation Oncology & Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne3002, Australia;2 Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville8006, Australia

Christopher P Daniels1 Division of Radiation Oncology & Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne3002, AustraliaCorrespondence[email protected]

Rodney J Ellis3 Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH44106, USA

Lee Ponsky4 Department of Urology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH44106, USA

Simon S Lo3 Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH44106, USA

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

RJ Ellis has received research funding from Elekta AB and Phillips. L Ponsky has received research grants from Accuray. SS Lo has received travel expenses and honorarium from Varian Medical Systems and Accuray and research support from Elekta AB. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2144/000112170

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer: What have we Learned from Prospective Trials and What Does the Future Hold?

Information for

Open access

Opportunities

Help and information

Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer: What have we Learned from Prospective Trials and What Does the Future Hold?

Financial & competing interests disclosure

Supplementary data

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature